Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action

Publisher： Karger

E-ISSN： 2296-5262|37|3|128-134

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.37, Iss.3, 2014-02, pp. : 128-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 2, 2015-01 ,pp. : 142-145

Bentham Science Publishers

Access to resources Recommend Favorite

A Near-Complete Response to Treatment with Gemcitabine plus nab®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-10 ,pp. : 711-717

Karger

Access to resources Recommend Favorite

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer

By  

Case Reports in Oncology, Vol. 5, Iss. 3, 2012-12 ,pp. : 687-692

Karger

Access to resources Recommend Favorite

Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine

By  

Oncology Research and Treatment, Vol. 38, Iss. 11, 2015-0 ,pp. : 596-603

Karger

Access to resources Recommend Favorite

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-09 ,pp. : 648-655

Karger

Access to resources Recommend Favorite